Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Older adults and newborn babies are among those most at risk, leading to serious cases of pneumonia, a high number of ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co ...

For older adults, this means that RSV isn’t just another respiratory virus, but a disease that can have severe consequences. In Asia, up to 80 per cent of older adults hospitalised with RSV ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older ...